Loading...
The Why, what, and How of the New FACT standards for immune effector cells
Novel cellular therapies outside of traditional hematopoietic stem cell transplantation or hematopoietic progenitor cell (HPC) therapy are currently under evaluation in clinical trials across the United States and around the world. Several cellular products, e.g., CD19-directed Chimeric Antigen Rece...
Saved in:
| Published in: | J Immunother Cancer |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5394615/ https://ncbi.nlm.nih.gov/pubmed/28428885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0239-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|